Australian Clinical Labs Ltd (ACL) - Cash Flow Conversion Efficiency

Latest as of December 2025: 0.416x

Based on the latest financial reports, Australian Clinical Labs Ltd (ACL) has a cash flow conversion efficiency ratio of 0.416x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$62.87 Million ≈ $44.48 Million USD) by net assets (AU$151.04 Million ≈ $106.87 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Australian Clinical Labs Ltd - Cash Flow Conversion Efficiency Trend (2016–2025)

This chart illustrates how Australian Clinical Labs Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Australian Clinical Labs Ltd debt and liabilities for a breakdown of total debt and financial obligations.

Australian Clinical Labs Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Australian Clinical Labs Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
HansBiomed Corporation KQ:042520	0.036x
SILENCE THERAP. SP.ADR/1 F:XRP2	N/A
Medeon Biodesign TWO:6499	-0.118x
Bourse Direct SA PA:BSD	0.089x
Hydratec Industries NV AS:HYDRA	0.127x
Kepler Weber S.A SA:KEPL3	0.071x
Launch Two Acquisition Corp. Class A Ordinary Shares NASDAQ:LPBB	-0.001x
Gyldendal A/S CO:GYLD-A	0.262x

Annual Cash Flow Conversion Efficiency for Australian Clinical Labs Ltd (2016–2025)

The table below shows the annual cash flow conversion efficiency of Australian Clinical Labs Ltd from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see Australian Clinical Labs Ltd market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-06-30	AU$171.98 Million ≈ $121.69 Million	AU$182.80 Million ≈ $129.34 Million	1.063x	0.00%
2024-12-31	AU$171.98 Million ≈ $121.69 Million	AU$182.80 Million ≈ $129.34 Million	1.063x	+18.39%
2024-06-30	AU$177.76 Million ≈ $125.78 Million	AU$159.59 Million ≈ $112.92 Million	0.898x	0.00%
2023-12-31	AU$177.76 Million ≈ $125.78 Million	AU$159.59 Million ≈ $112.92 Million	0.898x	+7.89%
2023-06-30	AU$172.67 Million ≈ $122.18 Million	AU$143.68 Million ≈ $101.66 Million	0.832x	0.00%
2022-12-31	AU$172.67 Million ≈ $122.18 Million	AU$143.68 Million ≈ $101.66 Million	0.832x	-31.88%
2022-06-30	AU$232.56 Million ≈ $164.55 Million	AU$284.09 Million ≈ $201.01 Million	1.222x	0.00%
2021-12-31	AU$232.56 Million ≈ $164.55 Million	AU$284.09 Million ≈ $201.01 Million	1.222x	-34.97%
2021-06-30	AU$81.91 Million ≈ $57.96 Million	AU$153.86 Million ≈ $108.87 Million	1.878x	0.00%
2020-12-31	AU$81.91 Million ≈ $57.96 Million	AU$153.86 Million ≈ $108.87 Million	1.878x	+27.37%
2020-06-30	AU$68.99 Million ≈ $48.81 Million	AU$101.74 Million ≈ $71.98 Million	1.475x	0.00%
2019-12-31	AU$68.99 Million ≈ $48.81 Million	AU$101.74 Million ≈ $71.98 Million	1.475x	+3536.33%
2019-06-30	AU$27.42 Million ≈ $19.40 Million	AU$1.11 Million ≈ $786.81K	0.041x	0.00%
2018-12-31	AU$27.42 Million ≈ $19.40 Million	AU$1.11 Million ≈ $786.81K	0.041x	-95.28%
2018-06-30	AU$5.46 Million ≈ $3.86 Million	AU$4.69 Million ≈ $3.32 Million	0.860x	0.00%
2017-12-31	AU$5.46 Million ≈ $3.86 Million	AU$4.69 Million ≈ $3.32 Million	0.860x	+163.80%
2017-06-30	AU$14.12 Million ≈ $9.99 Million	AU$4.60 Million ≈ $3.26 Million	0.326x	0.00%
2016-12-31	AU$14.12 Million ≈ $9.99 Million	AU$4.60 Million ≈ $3.26 Million	0.326x	--

About Australian Clinical Labs Ltd

AU:ACL Australia Diagnostics & Research

Market Cap

$245.52 Million

AU$347.00 Million AUD

Market Cap Rank

#15753 Global

#441 in Australia

Share Price

AU$1.84

Change (1 day)

-1.61%

52-Week Range

AU$1.84 - AU$3.12

All Time High

AU$5.09